Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Majalah Farmaseutik Indonesian Journal of Pharmacology and Therapy
Purwandityo, Ayuningtyas Galuh
Unknown Affiliation
Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Narrative Review: Efektivitas Sitikolin vs Asam Folat dalam Menurunkan Disabilitas Neurologis Pasien Stroke Iskemik Akut Purwandityo, Ayuningtyas Galuh; Ikawati, Zullies; Pinzon, Rizaldy Taslim
Majalah Farmaseutik Vol 20, No 1 (2024)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v20i1.83668

Abstract

Stroke adalah penyebab kedua kematian di seluruh dunia serta menyebabkan disabilitas fisik dan neurologis jangka panjang. Keparahan defisit neurologis dini adalah penentu yang paling penting dari hasil fungsional akhir pada stroke iskemik akut. Tujuan dari penelitian ini adalah membandingkan efektivitas penggunaan sitikolin dan asam folat dalam memperbaiki disabilitas neurologis pasien stroke iskemik akut. Penelitian ini dilakukan dengan cara narrative review dan dilakukan dalam empat tahap yaitu penentuan kata kunci, kriteria inklusi dan eksklusi, seleksi literatur, dan analisis hasil. Pencarian literatur dilakukan melalui database elektronik seperti PubMed, Scopus, Science Direct, Wiley Online Library dan Springer Link. Berdasarkan review yang dilakukan diperoleh data bahwa sitikolin terbukti neuroprotektor yang aman dan efektif diberikan pra, pasca serta pengobatan stroke jangka panjang sebab mampu menurunkan disabilitias neurologis. Pada penggunaan asam folat juga cenderung terbukti efektif untuk mencegah stroke, namun biasanya dikombinasi dengan vitamin B12 atau vitamin B6. Selain itu, data terkait fungsi asam folat dalam menurunkan disabilitas neurologis pasca stroke atau sebagai pengobatan jangka panjang masih sangat terbatas.
Anticoagulant use to treat VTE (venous thromboembolism) in pregnancy: a review Purwandityo, Ayuningtyas Galuh; Muhammad S. Finnegan; Mukarromah D. Putri; Muya Saroh; Nindita Rachmania; Riandita G. Putri
Indonesian Journal of Pharmacology and Therapy Vol 3 No 3 (2022)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.3238

Abstract

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a medical condition that occurs when a blood clot forms in a deep vein that major cause of pregnancy-related maternal death. As pregnancy progresses, the risk of hypercoagulability increases, fibrinogen, factors VII, VIII, X and VWF (Von Willebrand Factor), plasminogen activator inhibitor-1, plasminogen activator inhibitor-2 are increases and 40-60% protein S decreases. Therefore, anticoagulant drugs are the mainstay of therapy for patients with VTE. The review aimed to select the best anticoagulant for pregnancy women with VTE. A scoping review was used. The type of articles reviewed were original articles obtained from four electronic journal databases published within 2012-2021. The main therapeutic agent recommended for use in the prevention and treatment of VTE in pregnancy is low molecular weight heparin (LMWH). LMWH has better bioavailability than other anticoagulants, has a lower risk of maternal bleeding, thromboembolic, thrombocytopenia and osteoporosis. The use of LMWH is actually better, more comfortable and safety for patients.
Co-Authors Muhammad S. Finnegan Mukarromah D. Putri Muya Saroh Nindita Rachmania Riandita G. Putri Rizaldy Pinzon